First- and Second-Line Treatment Options in Lower-Risk MDS

Video

Hematologic oncology experts give an overview of first- and second-line treatment options for lower-risk myelodysplastic syndromes.

Related Videos
Debu Tripathy, MD
Lori A. Leslie, MD
Debu Tripathy, MD
Changchun Deng, MD, PhD
Parul N Barry, MD,
Ramez Kouzy, MD, MD Anderson
Hannah Walker-Mimms, MS
Hye Sook Chon, MD, gynecologic oncologist, Gynecologic Oncology Program, Moffitt Cancer Center
Elias Jabbour, MD
A panel of 4 experts on colorectal cancer
Related Content
Bruna Pellini, MD, of Moffitt Cancer Center and Research Institute

Pellini Discusses Immunotherapies and Current Limitations of ctDNA in Perioperative NSCLC

May 16th 2024
Article
Amin Nassar, MD, hematology/oncology fellow, Yale University; Elias Bou Farhat, MD, postdoctoral research fellow, Department of Medicine, Brigham and Women’s Hospital

Bou Farhat and Nassar on the Use of NGS Mutation Signature vs IHC for Identifying dMMR Tumors

April 29th 2024
Podcast
OncLive On Air Podcast Recap

Revisit Every OncLive On Air Episode From April 2024

May 13th 2024
Article
Elias Jabbour, MD, professor, medicine, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

FDA Approval Insights: Ponatinib in Ph+ ALL

April 8th 2024
Podcast
Naval G. Daver, MD

Commitments to AML Research Uncover Numerous Targets in Relapsed/Refractory Disease

May 9th 2024
Article
Harout Semerjian, CEO of GlycoMimetics

Uproleselan Plus Chemotherapy Misses OS End Point in R/R AML

May 6th 2024
Article